Biodexa Pharmaceuticals (BDRX) Corporate presentation summary

Company overview and strategy

• Listed on NASDAQ with a $5M market cap and a focus on rare GI oncology diseases.

• Operates a semi-virtual organization with near-term milestones and a funded Phase 3 program in FAP.

• Strategy centers on building a GI oncology pipeline, developing assets through early clinical stages, and partnering for late-stage development and commercialization.

Pipeline and clinical programs

• MTX230 (eRapa, rapamycin) is in Phase 3 for Familial Adenomatous Polyposis (FAP), supported by a $20M grant, with orphan designation in the US/EU.

• MTX230 also in Phase 2 for non-muscle invasive bladder cancer and completed Phase 1 in prostate cancer, showing safety and tolerability.

• MTX240 (molecular glue) is Phase 1-ready for GIST, with efficacy in resistant models and orphan status; first patient dosing targeted for 4Q26.

• MTX228 (tolimidone) is a Lyn kinase activator in Phase 2 for Type 1 Diabetes, with preclinical data supporting beta cell preservation.

Key clinical data and mechanisms

• MTX230 re-formulated for improved pharmacokinetics; Phase 2 FAP data showed 89% non-progression and 29% median polyp burden decrease in one cohort.

• MTX230 acts as an mTOR inhibitor, targeting pathways activated by APC mutations in FAP.

• MTX240 induces apoptosis in GIST by forcing PDE3a and SLFN12 complexation, independent of KIT/PDGFR mutations.

• MTX228 promotes beta cell survival via Lyn kinase activation, with preclinical models showing increased beta cell mass and improved glucose control.